CHRNB2

Across TCGA pan-cancer cohorts, CHRNB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHRNB2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher CHRNB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHRNB2 expression acts as an unfavorable survival marker.

PAAD, BRCA, and OV are the cancer types where CHRNB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.037	0.641	<.001	24	view →
BRCA	OS	Median	III,IV	0.140	0.833	<.001	24	view →
OV	OS	Median	II,III,IV	0.282	0.692	.014	18	view →
LIHC	DFS	Median	All	0.123	0.544	.014	12	view →
PRAD	DFS	Median	All	0.085	0.774	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHRNB2–PAAD (OS)

Open the PAAD breakdown →